74 results about "Hydrophobic matrix" patented technology

The invention provides an implantable membrane for regulating the transport of analytes therethrough that includes a matrix including a first polymer; and a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which when hydrated are not observable using photomicroscopy at 400× magnification or less. In one aspect, the homogeneous membrane of the present invention has hydrophilic domains dispersed substantially throughout a hydrophobic matrix to provide an optimum balance between oxygen and glucose transport to an electrochemical glucose sensor.

The present invention teaches a novel approach of creating biocmpatible surfaces, said surfaces being capable of functionally interact with biological material. SAid biocompatible surfaces comrise at least two comonents, such as a hydrophobic substratum and a macromolecule of hydrophilic nature, which, in a cooperativity, form together the novel biocoompatible surfaces. The novel approach is ased on contacting said hydrophobic substratum with a laterally patterned monomolecular layer of said hydrophilic and flexible macromolecules, exhibiting a pronounced excluded volume. The htus formed two component surface is, in respect to polarity and morphology, a molecularly heterogeneous surface. Structural features of said macromolecular monolayer (as e.g. the layer thickness or its lateral density) are determined by: i) the structural features of the layer forming macromolecules (as e.g. their MW or their molecular architecture) and ii) the method of creating said monomolecular layer (as e.g. by physi- or chemisorbing, or by chemically binding said macromolecules). The structural features of the layer forming macromolecules(s) is in turn determined by synthesis. AMount and conformation and thus also biological activity of biological material (as e.g. polypeptides) which contact the novel biocompatible surface, is determined and maintained by the cooperative action of the underlying hydrophobic substratum and the macromolecular layer. In this way it becomes possible to maintain and control biological interactions between said contacted polypeptides and other biological compounds as e.g. cells, antibodies and the like. Consequently, the present invention aims to reduce and/or eliminate the deactivation and/or denaturation associated with the contacting of polypeptides and/or other biological material to a hydrophobic substratum surface.

An enteric coated pharmaceutical extended release dosage form of a H+, K+-ATPase inhibitor giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is obtained by a pharmaceutical composition which comprises a core material of a hydrophilic or hydrophobic matrix, and the H+, K+-ATPase inhibitor and optionally pharmaceutically acceptable excipients. The dosage form may be administered once daily.

A novel miniaturized and highly automated method for the controlled printing of large arrays of nano- to femtoliter droplets is presented by actively transporting mother droplets over hydrophilic-in-hydrophobic micropatches. The proposed technology consists of single plate or double-plate devices where mother droplets can be actuated and hydrophilic-in-hydrophobic micropatches on one or both plates of the device where nano- to femtoliter droplets are printed. Due to the selective wettability of the more wettable hydrophilic micropatches in a hydrophobic matrix, large nano- to femtoliter droplet arrays are created when mother droplets are transported over these arrays. The parent droplets can be moved by different droplet actuation principles, for example, by using the principle of electrowetting-on-dielectric droplet actuation. We propose another method that uses two plates that are placed on top of each other while being separated by a spacer. One plate is dedicated to confirming and guiding of parent droplets by using hydrophilic patches in a hydrophobic matrix, while the other plate contains hydrophilic-in-hydrophobic arrays dedicated to the printing of nano- to femtoliter droplets. When the plate dedicated to parent droplet guiding is rotated over the plate dedicated to printing of nano- to femtoliter droplets, nano- to femtoliter droplets are dispensed inside the hydrophilic-in-hydrophobic array due to their selective wettability. All these proposed methods allow the parent droplets to be moved over the hydrophilic-in-hydrophobic arrays many times, providing unique advantages for performing bio-assays or miniaturized materials synthesis in nano- to femtoliter sized droplets. Upon the controlled evaporation of the dispensed droplets of solution, large arrays of the printed material can be generated on an automated way in seconds of time on a very flexible way. The method disclosed herein provides a distinct nano- to femtoliter droplet printing technique for a wide variety of applications such as protein- or cell-based bio-assays or printing of crystalline structures, suspensions of nanoparticles or components for microelectronics.

A method of making CNT films is described in which the film is washed with a mild acid treatment. The method generates a CNT film that is not sensitive to moisture or fluctuations in moisture. The method involves the use of anionic polysaccharides or anionic glycosaminoglycans such as hyaluronic acid, sodium salt, as aqueous dispersing agents and their modification to a hydrophobic matrix after deposition. In the course of conducting the work described here, we made the surprising discovery that washing with an aqueous acidic solution resulted in a decrease in resistance through the material. The invention also includes CNT composites made by the inventive methods and a CNT composite comprising CNTs and anionic polysaccharides or anionic glycosaminoglycans further characterized by a low cationic content and a high conductivity and/or small CNT particle size as measured by SEM.

Articles produced from hydrophobic polymers (e.g., polyethylene) are surface-coated with thin films of starch in order to render the surfaces hydrophilic. The thin coatings form on the surfaces of plastic objects when the objects are placed in contact with hot, aqueous solutions of starch. These starch coatings are adherent to the hydrophobic plastic surfaces under both wet and dry conditions, and they permit the surfaces to be uniformly wet with water. The coatings may be rendered even more adherent when wet by graft polymerizing the starch with a synthetic monomer. Resultant products have the potential for improved biocompatibility, improved compatibility with hydrophilic reagents, reduced build-up of electrostatic charge, reduced blocking, reduced friction, improved absorption of water-based dyes, and improved adhesion properties. The starch coatings are non-toxic, inexpensive and biodegradable.

An enteric coated hydrophobic matrix tablet for soluble, freely soluble and very soluble drugs.

A self-gelling tunable drug delivery system is disclosed. The self-gelling tunable drug delivery system is comprised of a hydrophilic matrix and a hydrophobic matrix.

A coating for an expandable portion of a catheter comprising a hydrophobic matrix and a dispersed phase is disclosed. The dispersed phase comprises a plurality of micro-reservoirs dispersed in the hydrophobic matrix, wherein the plurality of micro-reservoirs comprises a first active agent and a first biodegradable or bioerodable polymer. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided.

The present invention relates to a self-supporting interface dressing formed by a thin layer of a composition comprising a hydrophobic matrix and having through-holes. According to the invention, this hydrophobic matrix comprises, for 100 parts by weight of a styrene/saturated olefin/styrene triblock copolymer with a viscosity of between 0.2 and 2 Pa.s, as measured in a 10% (weight/weight) solution in toluene, from 400 to 1,220 parts by weight of a plasticizer, preferably a plasticizer oil, and from 0 to 720 parts by weight of petroleum jelly, it being additionally specified that the total quantity of plasticizer and of petroleum jelly is greater than or equal to 750 parts by weight, and the quantity of petroleum jelly is between 400 and 720 parts by weight when the quantity of plasticizer is between 1,000 and 1,220 parts by weight. Application to the treatment of wounds.

Provided herein is a multifunctional particle and methods of forming the same. The multifunctional particle includes a surface of the particle; a first moiety coupled to the surface and having at least one substantially hydrophobic appendage; and a second moiety coupled to the surface and having at least one appendage comprising a reactive functional group and a substantially hydrophilic repeating unit, whereby the particle is substantially superhydrophobic as a result of the substantially hydrophobic appendage, chemically reactive as a result of the reactive functional group, and migratory to a surface of a substantially hydrophobic matrix in which the particle may be included as a result of the substantially hydrophilic repeating unit. Additionally, antimicrobial functional groups may be coupled to the surface.

The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.

The present invention relates to a sustained release formulation comprising protein as an active ingredient, and a preparation method thereof. According to the present invention, the sustained release formulation contains protein drugs that are encapsulated in biodegradable hydrophobic matrices as pharmaceutically active forms by forming complexes with sulfated polysaccharides. The sustained release formulation prepared by the present invention can be used to effectively treat a disease without frequent injections by keeping the protein concentration at a sufficiently high level for a long period when injected in vivo once.